Effect of High Intensity Exercise Rehabilitation on Hepatic Fatty Acids (Liver Function), Insulin Sensitivity and Cardiovascular Risk in Patients With MASLD

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease worldwide, and is associated with obesity and the metabolic syndrome. Physical activity and lifestyle interventions are among the most recommended treatments for individuals with MASLD. In this RCT, we will evaluate the effect of combined exercise training strength and aerobic training versus strength and high intensity training (HIIT). The main outcome parameter is the severity of liver steatosis. Patients will be recruited at the fatty liver clinic of the UZ Gent.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Diagnosed with MASLD by ultrasound, CAP and/or biopsy

• Age between 18 and 75 years old

• No significant liver fibrosis (Fibroscan \< 7.5 kPa; if it is between \>7.5 and \<10, there must be absence of liver fibrosis in the biopsy)

Locations
Other Locations
Belgium
Ghent University Hospital
RECRUITING
Ghent
Contact Information
Primary
Patrick Calders, Prof. dr.
patrick.calders@ugent.be
0032498354766
Backup
Sander Lefere, dr.
sander.lefere@ugent.be
Time Frame
Start Date: 2024-04-26
Estimated Completion Date: 2026-03-15
Participants
Target number of participants: 92
Treatments
Active_comparator: Combined strength + aerobic training
The patients in this group will exercise for 14 weeks. It is a combination of strength and aerobic exercise.
Experimental: Combined strength + HIIT
The patients in this group will exercise for 14 weeks. The first 6 weeks consists of combined aerobic and strength exercise, following the protocol from the active comparator group.~They will switch to combined strength and HIIT exercise for the remaining 8 weeks.
Sponsors
Leads: University Ghent
Collaborators: University Hospital, Ghent

This content was sourced from clinicaltrials.gov